Short Interest in Knight Therapeutics Inc. (OTCMKTS:KHTRF) Rises By 62.2%

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 560,000 shares, an increase of 62.2% from the October 31st total of 345,200 shares. Based on an average daily trading volume, of 14,900 shares, the days-to-cover ratio is presently 37.6 days.

Knight Therapeutics Price Performance

Shares of Knight Therapeutics stock traded up $0.02 on Friday, reaching $3.75. 3,000 shares of the company’s stock were exchanged, compared to its average volume of 6,026. The firm’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.14. Knight Therapeutics has a 52 week low of $3.65 and a 52 week high of $4.55.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.